Monday morning my email inbox lit up. A Wall Street Journal article--both online and in the hard copy edition--about the FDA's unprecedented approval of three anti-myeloma drugs in less than a month was featured front and center. I had spoken by phone with the reporter who wrote the story for 30 minutes on Friday. I
A good friend of mine, long-lived myeloma survivor Paula Van Riper, was recently featured in an excellent Wall Street Journal article about the recent FDA approvals of Kyprolis and Pomalyst. The IMF's Medical Director, Dr. Brian Durie, is interviewed, along with Dr. David Siegel, chief of the myeloma division at John Theurer Cancer Center in
Do you remember my articles and posts about immunotherapies at this year’s ASCO in Chicago? How could you have missed them? I ran three articles on HelpWithCancer.org (HWC) this weekend and two more on this site. And that doesn’t include this morning’s multiple myeloma immuno specific post about the surprising new monoclonal protein, daratumumab.
Yesterday I provided you with a link to a Wall Street Journal article about the high cost of thalidomide, How Drug's Rebirth as Treatment For Cancer Fueled Price Rises: Once-Demonized Thalidomide Boosts Celgene's Sales; Patients See Costs Soar, by Geeta Anand.Anyone notice when this article was written? November 15, 2004! Six years ago patients were
Monday I wrote a brief article about how Revlimid was more expensive per pound than gold. The story was based on a suggestion I received by e-mail the previous week.I have received a number of e-mails and calls since Monday about the high cost of Revlimid. Frustration over the drug's cost is growing, fueled by